BLI | Repare Therapeutics (NYSE:BLI) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Repare Therapeutics (NYSE:BLI) from a hold rating to a buy rating in a research report sent to investors on Tuesday, reports.Zacks Investment Research currently has $84.00 price objective on the stock.According to Zacks, “Berkeley Lights a Digital Cell Biology company.It focuses on development […] Dakota Financial News